# Atavistik Bio

Atavistik Bio has 1 open role live as of 5 September 2026, 0 of which were posted in the last 7 days. 0% of Atavistik Bio's open roles are remote, and Atavistik Bio hires most in Cambridge, United States (1 role). These figures are read directly from Atavistik Bio's Lever careers page and were last checked on 5 September 2026.

Data source: ReqHunt — read from Atavistik Bio's Lever careers page on 5 September 2026. https://reqhunt.com/company/atavistik-bio

## Hiring snapshot

- Open roles: 1 (as of 5 September 2026)
- Posted in the last 7 days: 0
- Posted in the last 30 days: 0
- Remote share: 0% of open roles
- Change in open roles, last 30 days: -50%
- Most recent posting: 3 June 2026
- First tracked by ReqHunt: 5 August 2026
- Hiring status: hiring paused

Posting dates come from the company's own applicant tracking system, not from when ReqHunt first saw the role.

## ReqHunt Remote Index

Atavistik Bio is not scored: fewer than 10 open roles. Methodology: https://reqhunt.com/remote-index

## Where Atavistik Bio hires

Remote roles are counted here too, by the scope they are open to.

- Cambridge, United States: 1 roles

## Atavistik Bio role mix

By function: engineering 100%, product & design 0%, sales 0%, operations 0%, other 0%.
By seniority: junior 0%, mid 0%, senior 0%, lead and above 100%.

## Common questions

**Is Atavistik Bio hiring?** Yes — Atavistik Bio has 1 open role as of 5 September 2026, 0 of them posted in the last 7 days.

**Is Atavistik Bio hiring remotely?** No remote roles are currently open at Atavistik Bio — all 1 live role is tied to a location.

**Where does Atavistik Bio hire most?** Atavistik Bio hires most in Cambridge, United States (1).

**Is Atavistik Bio's hiring accelerating or slowing?** slowing — Atavistik Bio's open-role count is down 50% over the last 30 days.

## Open roles at Atavistik Bio

Showing 1 of 1 live roles, newest first.

- **Sr. Director, Biostatistics** — Cambridge, MA · Clinical · posted 93 days ago

## About Atavistik Bio

We are advancing multiple programs with best-in-class potential, including our lead asset, ATV-1601, an oral allosteric AKT1-selective inhibitor for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and advancing a JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms.

---

Data source: ReqHunt — read from Atavistik Bio's Lever careers page on 5 September 2026. https://reqhunt.com/company/atavistik-bio
Human-readable version: https://reqhunt.com/company/atavistik-bio. Attribution required when this data is reproduced or summarised.